RxDoctor Payments DataLook up a doctor →

Kevin Kimata, MD

Neurology · Honolulu, HINPI 1598763781

Payments from drug & device makers

$23,658in general payments, 2019–2025

Across 1,133 payments — averaging $20.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • UCB, Inc.$3K
  • Teva Pharmaceuticals USA, Inc.$2K
  • AstraZeneca$1K
  • Amgen$937
  • Neurocrine Biosciences, Inc.$818
  • plus $12K from 53 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)178$3,731
UCB, Inc.106$2,746
Teva Pharmaceuticals USA, Inc.110$1,998
AstraZeneca39$1,001
Amgen(2 entities)37$937
Neurocrine Biosciences, Inc.29$818
Biogen35$799
Sunovion Pharmaceuticals Inc.70$795
Pfizer62$783
Lundbeck LLC32$749
Eisai Inc.33$726
Harmony Biosciences LLC22$616
Jazz Pharmaceuticals Inc.20$522
Argenx US, Inc.20$468
SK Life Science, Inc.25$456
Neurelis, Inc.26$455
Tanabe Pharma America, Inc.22$450
Amneal Pharmaceuticals LLC23$440
Novartis22$417
Acorda Therapeutics, Inc17$404
Acadia Pharmaceuticals Inc18$367
CSL Behring14$276
Biohaven Pharmaceutical Holding Company Ltd.19$265
Kyowa Kirin, Inc.14$263
EMD Serono, Inc.11$255
Otsuka America Pharmaceutical, Inc.11$254
Takeda Pharmaceuticals U.S.A., Inc.9$253
Upsher-smith Laboratories LLC12$231
TG Therapeutics, Inc.7$172
Alnylam Pharmaceuticals Inc.6$151
Bristol Myers Squibb7$138
Grifols USA, LLC6$130
Adamas Pharmaceuticals, Inc.6$128
Sanofi5$125
Vanda Pharmaceuticals Inc.3$105
Lilly USA, LLC4$100
Biohaven Pharmaceuticals, Inc.4$86
Avanir Pharmaceuticals, Inc.4$82
Livanova USA, Inc.4$79
Catalyst Pharmaceuticals, Inc.3$74
Kowa Pharmaceuticals America, Inc.4$71
Genentech, Inc.3$67
Akcea Therapeutics, Inc.2$56
Supernus Pharmaceuticals, Inc.3$55
Axsome Therapeutics, Inc.2$54
Merz Pharmaceuticals, LLC2$52
Arbor Pharmaceuticals, Inc.3$50
Mallinckrodt Hospital Products Inc.2$46
Merz North America, Inc.2$45
Insightec,inc2$44
Sarepta Therapeutics, Inc.2$43
Medtronic2$43
Amarin Pharma, Inc.2$37
Genentech USA, Inc.2$37
Otsuka Pharmaceutical Development & Commercialization, Inc.1$28
Amylyx Pharmaceuticals, Inc.1$24
ITF Therapeutics LLC1$22
Greenwich Biosciences, Inc.1$19
Cala Health, Inc.1$18

How this compares

$23,658 in reported general payments places this provider in the 85th percentile of 54 neurology providers in Hawaii.

See all neurology providers in Hawaii →

Medicare billing

Part B allowed, 2024
$183,954
Medicare patients
385
Services billed
10,097

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Honolulu

See the full list for Hawaii →

Where these figures come from

Is this you, or does something look wrong? →